All In Biotech

Drug Trial Radar · NCT06678399

Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery

Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery

Last checked: Nov 19, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

91

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Oct 1, 2026

Study completion Jan 1, 2027

Sponsor

Lead sponsor
KelifarmaIndustry
Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to evaluate KELI-101 versus placebo for the prevention of acute kidney disease leading to chronic kidney disease in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive KELI-101, while the other half will receive a placebo.

Conditions

  • Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery

Interventions

  • KELI-101Drug

    KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.

  • Vehicle (placebo)Other

    Plasmalyte

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAE)Time frame: From KELI -101 administration up to Day 90
  2. Ratio of the acute kidney disease (AKD) leading to chronic kidney disease (CKD)Time frame: From baseline to Day 90

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.